Novo nornord Victoza extended indications obtain FDA approval
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
today, the United Statesthe FDA announced(http:// that it has approved the expansion of Victoza (liraglutide) in thecompany(http://to extend the indications of diabetes for people with type 2 diabetes over the age of 10this is the first new drug(http://to treat non-insulin type 2 diabetes in pediatric patients since metformin was approved in 2000 for the treatment of type 2 diabet
es in childrenLiraglutide is a glucagon-like peptide-1 (GLP-1) analogue developed by Novo Nordiskliraglutide has a similar effect to GLP-1, slowing the digestive process, preventing the liver from producing too much glucose, and helping the pancreas produce more insulinThedrug(http://was approved in 2010 to treat adults with type 2 diabetesThis approval is based primarily on the results of a clinical trial with placebo control in clinical trials of liraglutide in adult patients (http:// and in pediatric patients over 10 years of age 134 pediatric patients were treated with liraglutide or a placebo in the trial In the liraglutide group, 64 percent had a reduction of more than 7 percent of hbA1c levels, compared with 37 percent in the placebo group HbA1c is a common detection (http:// to assess patients' diabetes control levels Whether the patient received insulin therapy at the same time was independent of the test results
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
